Glucose degradation products in peritoneal dialysis solution impair angiogenesis by dysregulating angiogenetic factors in endothelial and vascular smooth muscle cells

Clin Exp Nephrol. 2022 Dec;26(12):1160-1169. doi: 10.1007/s10157-022-02272-3. Epub 2022 Sep 7.

Abstract

Background: The accumulation of glucose degradation products (GDPs) during peritoneal dialysis (PD) can lead to immature angiogenesis in the peritoneum. However, the effect of GDPs on angiogenesis, at concentrations observed in dialysate effluent, has not been widely investigated. We do not know how the inflammation observed in PD-related peritonitis affects angiogenesis of the peritoneum.

Methods: Human umbilical vessel endothelial cells (HUVEC) and human umbilical aortic smooth muscle cells (HUASMC) were used to examine the response to the three main GDPs found in peritoneal dialysate (methylglyoxal (MGO), 3-deoxyglucosone (3-DG), and 5-hydroxymethylfurfural (5-HMF). Supernatant from lipopolysaccharide (LPS)-activated murine macrophage cell lines (RAW 264.7 cells) were used to stimulate angiogenesis in the peritoneum. Changes in the expression of vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor B (PDGFB) in HUVEC, and PDGF-receptor beta (PDGF-Rβ) in HUASMC, were examined by real-time PCR, Western blot, and ELISA.

Results: In HUVECs, the expression of PDGFB mRNA and protein were decreased by exposure to MGO, 3-DG, and 5-HMF at concentrations observed in dialysate effluent. A subsequent decrease in secreted PDGF-BB was observed. In HUASMCs, MGO and 5-HMF increased the expression of VEGF-A mRNA and protein, while 5-HMF decreased the expression of PDGF-Rβ. VEGF-A is upregulated, and PDGF-Rβ is downregulated, by conditioned medium of LPS-stimulated macrophages in HUASMCs.

Conclusions: The GDPs of PD effluent cause an imbalance of angiogenic factors in endothelial cells and vascular smooth muscle cells that may lead to immature angiogenesis in the peritoneum.

Keywords: Endothelial cell; Glucose degradation products; Impaired angiogenesis; Vascular smooth muscle cell.

MeSH terms

  • Angiogenesis Inducing Agents*
  • Animals
  • Dialysis Solutions* / pharmacology
  • Endothelial Cells / metabolism
  • Glucose* / metabolism
  • Glucose* / pharmacology
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Lipopolysaccharides / pharmacology
  • Magnesium Oxide / metabolism
  • Mice
  • Muscle, Smooth, Vascular / chemistry
  • Myocytes, Smooth Muscle / chemistry
  • Neovascularization, Pathologic* / metabolism
  • Peritoneal Dialysis* / adverse effects
  • Peritoneum / metabolism
  • Proto-Oncogene Proteins c-sis / metabolism
  • Pyruvaldehyde / metabolism
  • Pyruvaldehyde / pharmacology
  • RAW 264.7 Cells
  • RNA, Messenger / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inducing Agents
  • Dialysis Solutions
  • Glucose
  • Lipopolysaccharides
  • Magnesium Oxide
  • Proto-Oncogene Proteins c-sis
  • Pyruvaldehyde
  • RNA, Messenger
  • Vascular Endothelial Growth Factor A